Abstract: Small cell neuroendocrine carcinoma (SCNEC) of the uterine cervix is a rare but extremely aggressive tumor. While high-risk human papillomavirus (HPV) is involved at an early stage of oncogenesis in many tumors, additional driving events have been postulated to facilitate the progression of SCNECs.
D
espite overall declines in incidence rates, cervical cancer is the second or third most common cancer in women with ∼0.5 million cases worldwide. In the United States, ∼12,990 new cases were diagnosed in 2016, with roughly 4120 deaths. 1,2 Small cell neuroendocrine carcinoma (SCNEC) of the cervix is a rare and highly aggressive neoplasm, accounting for 1% to 2% (range, <5%) of all cervical tumors. [3] [4] [5] [6] Most patients present at an advanced stage at the time of hysterectomy. Compared with stage comparable squamous cell carcinoma or endocervical adenocarcinoma, SCNEC is more likely to have distant metastasis and recurrence. 4, 7, 8 The main management modality of SCNEC includes surgery, chemotherapy, and radiation therapy. [9] [10] [11] SCNEC can recur within months after complete surgical resection with no residual disease. Despite extensive treatment, 5-year survival rates for SCNEC of all stages still vary from 25% to 39%, with poorer survival in higher stage disease. [12] [13] [14] [15] [16] Thus, there is a need for novel approaches to understand and treat this tumor.
Histologically identical to its counterparts at other sites such as the lung, SCNEC of the cervix is composed of monotonous small cells with enlarged ovoid hyperchromatic nuclei, nuclear molding, finely stippled chromatin, inconspicuous nucleoli, and scanty cytoplasm. 5, 14 Abundant mitotic figures and apoptotic bodies, extensive necrosis, and crush artifacts are also characteristic features. The vast majority of SCNECs of the cervix are etiologically associated with high-risk human papillomavirus (HPV). 5, 17, 18 Similar to other HPV-related malignancies, 19 oncoproteins E6 and E7 are required for the initiation and upkeep of SCNECs. While high-risk HPV is involved at an early stage of oncogenesis, additional driving events, including genetic and epigenetic alterations, have been postulated to facilitate the progression of SCNECs. Loss of heterozygosity (LOH) has been reported to be a frequent genetic event in SCNECs. In 1 study, 8 of 15 cases displayed LOH at various 3p loci (3p14, 3p21, and 3p24) and 1 tumor demonstrated LOH on 17p (TP53 locus). 20 Currently, cell signaling pathway inhibitors, angiogenesis inhibitors, apoptosis promoters, and immunotherapies have been tested for SCNEC of the lung. 21 Accordingly, the potential application of these targeted therapies to cervical SCNECs relies on identification of genetic alterations that are amenable to such therapies in these tumors. Using whole exome sequencing, a recent study demonstrated recurrent mutations in ATRX, EBRR4, and in AKT/mTOR signaling pathway genes including NF1, PTEN, RICTOR, and TSC2 in SCNECs of uterine cervix. 22 In another study of cervical SCNECs, sequencing of mutational hotspots within 50 cancer-related genes revealed recurrent mutations in PIK3-CA, KRAS, and TP53 genes. Of the 44 patients, 48% had at least 1 mutation for which some form of targeted therapy could be considered. 23 However, the former study identified a mutational profile that appears to be different from that of HPV-related malignancies. The latter study only captured somatic changes in a limited panel of 50 genes which assessed only hotspot mutations. Given that the available data on SCNECs is limited and that there might be differences in the spectrum of genetic alterations encountered in different studies, we performed next-generation sequencing using a larger gene panel on a set of SCNECs of the cervix collected from several institutions, with the goal of identifying genetic alterations that are amenable to targeted therapy.
MATERIALS AND METHODS

Case Selection
Cases were identified in the files of the authors' institutions (4 from Johns Hopkins Hospital, 2 from Mayo Clinic, 2 from the University of Alabama at Birmingham, and 2 from the Ohio State University Wexner Medical Center). Histologic sections of these cases were rereviewed by 3 pathologists (D.X., G.Z. and B.M.R.) to confirm the diagnosis. The study was approved by the Institutional Review Board at the Johns Hopkins Hospital.
Immunohistochemistry and In Situ Hybridization
Immunohistochemical staining was performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections as previously described. 19 Markers used included: p16 (INK4a) (mouse monoclonal, prediluted; Ventana, Tucson, AZ), synaptophysin (mouse monoclonal, 1:400 dilution; Novacastra/Leica Biosystems Inc., Buffalo Grove, IL), chromogranin (mouse monoclonal, prediluted; Ventana), and p53 (mouse monoclonal, prediluted; Ventana). In situ hybridizations (ISHs) were performed using a high-risk HPV RNA probe solution (RNAscope, HPV 
DNA Extraction
Paraffin-embedded tumor tissues, identified by hematoxylin and eosin staining of adjacent sections (tumor elements account for > 70% of section area), were macrodissected, and genomic DNA was extracted using a QIAamp DNA FFPE Tissue Kit with an adapted protocol (Qiagen, Valencia, CA). Briefly, slides bearing paraffin-embedded tissue were baked at 68°C for 20 to 30 seconds; the tissue was deparaffinized 3 times with xylene, and residual xylene was removed by washing through serial dilutions of ethanol. The tumor tissue was separated from adjacent normal tissue and placed in a tube allowing for complete evaporation of residual ethanol. The tissue pellet was resuspended in buffer ATL with added proteinase K. The rest of the procedure followed the manufacturer's instruction.
Polymerase Chain Reaction and Sanger Sequencing
Polymerase chain reaction (PCR)-based detection and typing of HPV has been described previously. 24, 25 In brief, the samples with undetected high-risk HPV by ISHs were checked for DNA integrity by amplifying β-globin as a housekeeping gene using the following primers: PC04, 5′-CAACTTCATCCACGTTCACC-3′; GH20: 5′-GAA GAGCCAAGGACAGGTAC-3′. The size of this PCR product is 268 base pairs (bp). The DNA samples with positive test results for β-globin were subsequently studied using HPV consensus primers MY09 (5′-CGTCCMAR RGGAWACTGATC-3′) and MY11 (5′-GCMCAGGG WCATAAYAATGG-3′). In the above primer sequence, M stands for A or C; R, for A or G; W, for A or T; and Y, for T or C. These primers amplified a broad spectrum of HPVs by flanking the conserved region L1 open reading frame. The PCR products (∼450 bp) amplified by MY09/ MY11 primers were diluted 10 times and used as the templates of a second PCR amplification (nested PCR) with another pair of primers, GP05 (5′-TTTGTTACTG TGGTAGATAC-3′) and GP06 (5′-GAAAAATAAACT GTAAATCA-3′), flanking an ∼150 bp fragment within the L1 open reading frame. The GP05/GP06 nested PCR products were subjected to direct DNA Sanger sequencing to analyze the HPV type. One tumor (case 1) with ISHdetected HPV 18 was used as positive control.
were added by ligation and the fragments were enriched by PCR (10 cycles). Each library was then hybridized to a SureSelect custom panel 2.8M bait set (Agilent) according to the manufacturer's protocol. The panel was originally designed as a clinical leukemia panel, and covered 637 genes important in the oncogenesis of both leukemia and solid tumors. The gene list is available upon request. After stringent washing the captured DNA was amplified with 12 cycles of PCR per manufacturer's protocol. The size and concentration of captured DNA custom was assessed using a Tapestation 2200 (Agilent). Captured samples were pooled and sequenced on a single HiSeq flow cell on a HiSeq. 2500 (Illumina), using a 2×100 bp PE Rapid Run v2 protocol.
Data Analysis
All reads were aligned to the human genome (GRCh37.p13/hg19), using the Burrows-Wheeler alignment algorithm. The final Binary Alignment Map file was used for variant calling with our custom variant caller pipeline, which called variants directly from the Binary Alignment Map file with multiple filters, including a filter of > 4 mutant reads in both directions, a common single nucleotide polymorphism (SNP) filter, and a strand bias filter. In addition, a filter based on a pool of normal FFPE tissue were applied, where variants with variant allele frequency (VAF) falling within 3 SD from mean VAF seen in a pool of normal FFPE tissues, were filtered out. Finally, the Broad Institute Integrated Genome Viewer was used to visually inspect all the variants called by the pipeline, variants with low-quality score (median quality score, <30) were excluded in this step. Two strand bias scores were calculated: the first 1 (SB1) considered only strand bias in variant reads: MAX (Var+, Var−)/(Var++, Var−); the second (SB2) adjusted variant calls for inherent strand bias:
A variant call passed the strand bias filter if either SB1 ≥ 0.7 and/or 2.0 ≥ SB2 ≥ 0.5. The sequencing mean coverage exceeded 300 reads in > 94% of all regions. Given the estimated tumor cellularity is above 90% of all the cases, we used a VAF filter of 10%. All variants were separated into 3 categories based on VAF, dbSNP, and COSMIC database annotation: (1) pathogenic: loss of function mutations or hotspot mutations based on COSMIC database; (2) likely germline: 40% ≤ VAF ≤ 60% with or without dbSNP annotation, but not fulfilling the criteria as pathogenic; (3) variants of uncertain significance (VUS): other variants.
RESULTS
Clinicopathologic Features of SCNEC
Clinicopathologic features are summarized in Table 1 . The patients ranged in age from 28 to 68 years (mean, 45.6 y; median, 40.5 y). Tumor size ranged from 1.3 to 10.0 cm (mean, 5.4 cm; median, 4.5 cm). Tumors were composed of monotonous cells with enlarged hyperchromatic nuclei, nuclear molding, scanty cytoplasm, and numerous mitotic figures and apoptotic bodies (Figs. 1A, B) . Characteristic neuroendocrine features included finely stippled chromatin, inconspicuous nucleoli, and Rosette-like structures (Fig. 1C) . Extensive crush artifact was frequently present. At the time of hysterectomy, lymph node metastases were identified in 5 cases. Lymph-vascular space invasion was commonly seen, even for the cases with a negative lymph node dissection. In addition to classic morphologic features, the diagnosis of SCNEC was supported by synaptophysin expression in all tumors (Table 1 and Fig. 1D ). In addition, 9 tumors have some degree of chromogranin expression which varied from focal to diffuse. All tumors exhibited diffuse/strong p16 Fig. 1E ). By ISH, HPV 18 was detected in 5 tumors, of which 4 were detected by RNA probe (Fig. 1F ) and 1 by DNA probe. High-risk HPV mixed RNA probe solution (covering 18 high-risk HPV subtypes) failed to detect HPV in the 5 tumors with undetectable HPV 18. In addition, for 1 of these tumors (case 2), the wide spectrum DNA probe also failed to detect HPV. To further assess for the presence of HPV in 5 tumors with undetected high-risk HPV by ISHs, PCR, a gold standard method for detecting HPV, was used. This analysis was technically successful in 3 of these 5 cases (amplification of β-globin) as well as in the positive control with ISH-detected HPV 18 (case 1; Figs. 2A, B) , 2 of the 3 successfully tested tumors had HPV detected by PCR, case 4 with HPV 35 (Fig. 2C) , and case 10 with HPV 18 (Fig. 2D) ; case 9 had no PCRdetectable HPV (Fig. 2A) .
Somatic Mutational Profile of SCNEC Table 1 and Figure 3 summarize the pathogenic variants and VUS in the 10 tumors. Detailed information about these variants is described in a Supplementary Table (Supplemental Digital Content 1, http://links.lww.com/PAS/A594). At least 1 pathogenic variant was detected in 8 tumors (Fig. 3A) . Four PIK3CA mutations, p.G106A, p.N345T, p.E545K (Fig. 3B) , and p.E545D, were detected in 3 tumors, of which 2 also harbored TP53 mutation. Oncogenic tyrosine kinase pathway mutations involving KRAS (p.G12V) and Erbb2 (p.R663Q) were also detected in cases 7 and 1, respectively. The tumor with Erbb2 mutation also had ARID1B (p. K2043fs) and BCL6 (p.W375C) mutations (case 1). BRCA1 (p.T367I) and BRCA2 (p.Q1187fs) mutations (Fig. 3C) were also detected individually in 2 tumors (cases 5 and 3, respectively). Activating oncogenic mutations or tumor suppressor inactivating mutations in MYC, NOTCH1, NCOA3, PTEN, and RB1 were identified in the tumors that also harbored other mutations. Interestingly, despite the presence of many VUS, no clinically relevant and actionable somatic mutations in the 637-gene panel were identified in 2 tumors (cases 8 and 10).These 2 tumors displayed classic morphologic features seen in SCNECs ( Supplementary  Figs. 1, 2 , Supplemental Digital Content 2 and 3, http:// links.lww.com/PAS/A595 and http://links.lww.com/PAS/ A596).
TP53 Mutations in SCNEC
Four tumors harbored TP53 somatic mutations (Table 1) . One tumor (case 4) had TP53 mutations (p.80fs and p.P80L) and notable mutations in 3 other genes:
PIK3CA (p.G106A and p.E545D), PTEN (p.G132D and p.F241S), and RB1 (p.S751fs). This tumor demonstrated complete absence of p53 expression, consistent with the "null" pattern of aberrant/mutation-type p53 expression (Figs. 4A, B) . Insertion of nucleotides AG in the codon 80 of TP53 gene lead to frameshift mutation (Fig. 4C) , premature translation termination, and p53 protein truncation that is not recognized by the p53 antibody. The second TP53-mutated tumor (case 2) harbored somatic mutations of TP53 (p.C238W), c-Myc (p.A199T), and NOCA3 (p.Q1239_1241del). This tumor demonstrated aberrant/mutation-type p53 overexpression, consistent with a missense mutation (Figs. 5A-C) . The presence of > 90% frequency of mutant TP53 allele was indicative of a biallelic pattern. A third tumor (case 9) with somatic mutations of TP53 (p.C275Y) and PIK3CA (p.N345T) also had aberrant/mutation-type p53 overexpression. Interestingly, these 3 TP53-mutated tumors were all from patients older than 60 years. HPV was detected in 1 of these TP53-mutated tumors (HPV 35 in case 4 by PCR but not ISH). Of interest, HPV 18 was detected in a tumor from a 29-year-old woman (case 3), which had TP53 p.E271Q mutation as well as somatic mutations of BRCA2 (p.Q1187fs) and NOTCH1 (p.Q2315*nonsense). Unlike the other 3 TP53-mutated tumors, the p53 expression pattern in this tumor was a normal/wild-type result.
Clinical Outcome of Patients With SCNEC
It has been well documented that SCNECs display highly aggressive behavior and thus, very poor prognosis. In fact, 4 patients in the current study died of disease at intervals ranging from 4 to 27 months after hysterectomy (cases 5, 8, 9, 10). These included 1 patient with somatic mutations of TP53 and PIK3CA; 1 patient with BRCA1 mutation and 2 patients with no detectable critical mutations in this gene panel. One patient (case 2, TP53, c-Myc, NCOA3) developed distant metastasis 2 months after hysterectomy and another patient (case 1, Erbb2, ARID1B, BCL6) had distant metastasis 13 months after hysterectomy. One patient (case 7, KRAS mutation) developed a postradiation pelvic bone chondroblastic osteosarcoma after a long disease-free survival (126 mo). Follow-up information was not available for 3 patients.
DISCUSSION
SCNEC of the uterine cervix is a rare but extremely aggressive tumor, with a very high mortality even among patients diagnosed with early stage disease. 6, 16 Because of its rarity, there is a lack of treatment guidelines based on prospective clinical trials. Thus, given the histologic similarity to SCNEC of the lung, the therapeutic approach for cervical SCNEC, such as the combination of chemotherapeutic reagents cisplatin and etoposide, is based on that used for pulmonary tumors. Early stage cervical SCNEC is usually treated by radical hysterectomy followed by adjuvant chemotherapy or concurrent chemoradiation. 27 Definitive concurrent chemoradiation, sometimes preceded by neoadjuvant chemotherapy and followed by adjuvant chemotherapy, has been used for locally advanced disease, and palliative chemotherapy for metastatic disease. 28 However, the high recurrence rate and the very poor prognosis warrant development of novel therapeutic options to treat SCNEC of the uterine cervix, including identification of molecular alterations that are amenable to targeted therapy.
The molecular genetic investigation of SCNECs of different organs has revealed some common altered molecular pathways that can be targeted in clinical trials. 21 This observation has broadened the spectrum of therapeutic options for SCNECs, regardless of the primary site of origin. While SCNECs of various sites have essentially similar histologic features, those arising in the cervix have an association with high-risk HPV and HPV 18 in particular, with HPV 18 detection rates in cervical SCNECs varying from 40% to 90%. 3, [29] [30] [31] All of our tumors demonstrated diffuse p16 expression. High-risk HPV was detected in 7 of 10 tumors overall and 7 of 8 fully successfully tested tumors.
HPV 18 was identified in 6 tumors (5 by ISH and 1 by PCR) and HPV 35 was detected in 1 tumor (by PCR). Since PCR amplification failed in 2 cases, the actual high-risk HPV frequency could be higher.
In this study, 3 tumors harbored TP53 somatic mutations which were correlated with an aberrant immunohistochemical staining pattern and 1 additional tumor with a TP53 mutation had a wild-type p53 expression pattern. Since the high-risk HPV viral oncoprotein E6 has the ability to neutralize the function of p53, the majority of high-risk HPV-related cervical cancers including SCNECs would be expected to have a wild-type TP53 gene. However, 1 study has shown that TP53 mutation occurred in 62.5% of cervical SCNECs, 32 while others have not observed this. 33, 34 Of note, those data derived from hotspot-based mutational analysis might underestimate the actual percentage of tumors with TP53 mutation. 23 Somatic mutations of TP53 were originally thought to be required in the absence of an HPV-encoded gene product E6 that mediates loss of p53 function. [35] [36] [37] Subsequent studies have demonstrated that TP53 mutation can occur regardless of HPV status. 38, 39 Our study demonstrated a case with TP53 mutation and diffuse p16 expression but no detectable high-risk HPV by both ISH and PCR methods. This observation raises the possibility of 2 different pathways to developing SCNEC in the FIGURE 4. SCNEC with aberrant loss of p53 expression associated with TP53 frameshift mutation (case 4). The tumor (A, hematoxylin and eosin) demonstrates aberrant/mutation-type complete loss of p53 expression ("null" pattern, B) because truncated p53 protein cannot be recognized by the p53 antibody. C, Insertion of nucleotides AG in the codon 80 of TP53 gene lead to frameshift mutation, premature translation termination and p53 protein truncation.
uterine cervix: a more common 1 that is high-risk HPVdriven and a less common 1 that is p53-driven in the absence of high-risk HPV with a similar mechanism to that of lung SCNECs. The combination of diffuse p16 expression and TP53 mutation in tumors unrelated to high-risk HPV is well-known, indicating that diffuse p16 expression by itself cannot be equated to the presence of high-risk HPV in a tumor. 40, 41 These pathways and the relationships between TP53 mutation and the presence or absence of high-risk HPV in SCNEC warrant further investigation in a larger number of tumors.
Four PIK3CA mutations G106A, N345T, E545K, and E545D were detected in 3 tumors in this study. Consistent with these findings, 18% (8/44) of SCNECs harbored PIK3CA mutation, the most frequent alteration, in a hotspot-based study. 23 As a known oncogene, PIK3-CA is located at chromosome 3q26 which encodes the p110α catalytic subunit of phosphatidylinositol 3-kinase (PI3K). 42 Commonly disrupted across different cancer types, PI3K/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway regulates cell proliferation, differentiation, quiescence, apoptosis, longevity, and oncogenesis. 43, 44 It has been demonstrated that PIK3CA plays a critical role in HPV-induced carcinogenesis, evidenced by the observation that activation of the PI3K/ AKT/mTOR pathway through PIK3CA regulates various transformed phenotypes as well as growth and differentiation of HPV-immortalized cells. 45 In fact, PIK3CA is thought to be one of the most frequently mutated genes in HPV-related cancers including cervical squamous cell carcinoma, endocervical adenocarcinoma, and HPVpositive head and neck tumors. [46] [47] [48] One patient in this cohort had an E545K mutation, one of the most common PIK3CA mutations. Other PIK3CA mutations including G106A, N345T, and E545D are less common but have been reported previously. PIK3CA mutations constantly activate downstream effectors such as PDK1 and AKT that promote and sustain cellular transformation. Similarly, loss of PTEN function through somatic mutations in SCNECs causes excessive PIP3 at the plasma membrane, recruiting, and activating a subset of pleckstrin homology domain-containing proteins to the cell membrane including phosphoinositide-dependent kinase-1 and AKT family members. 49 A Notch1 mutation, not previously reported in SCNEC, was found in 1 tumor that did not have PIK3CA mutation. One function of mutant Notch1 is to activate c-Myc and PI3K-AKT-mTOR1 signaling through transcriptional repression of PTEN and promoting growth factor receptor signaling to PI3K-AKT. 50 Taken together, the SCNECs bearing these mutations might be sensitive to mTOR or AKT inhibitor treatment, a potential targeted therapy for this highly aggressive disease.
KRAS mutation, c.35G > T (G12V) was identified in 1 patient who was alive for > 10 years. Interestingly, a previous study demonstrated that KRAS mutations were present exclusively in endocervical adenocarcinomas, but not squamous cell carcinoma. 47 Another study showed that KRAS mutations were seen exclusively in destructively invasive endocervical adenocarcinomas (pattern B and pattern C subgroups) and correlated with advanced stage at presentation (FIGO stage II or higher). 51 KRAS mutations have been reported in SCNECs. Importantly, a patient with a KRAS mutation (c.35G > A p.G12D) was treated with the MEK inhibitor trametinib and had a complete radiologic response after 3 cycles. 52 Different from the G12D mutation that activates both PI3K/AKT and MAPK pathways, the patient in the current study harbored a G12V KRAS mutation that triggers the MAPK cascade and leads to loss of the ability to bind to and signal through PI3K/AKT/mTOR. 53 Theoretically, a patient whose tumor harbors a G12V KRAS mutation may respond better, compared with G12D, to MEK inhibitors. 23 Another interesting somatic mutation identified in this study is ERBB2 p.R678Q mutation. This somatic mutation has been previously described in breast cancer. However, R678Q mutation showed no functional effect in an in vivo and in vitro model system. 54 Therefore, a role of ERBB2 R678Q mutation in the development of SCNECs remains elusive. Similarly, further evaluation of the biological significance of somatic mutations in c-Myc, ARID1B, RB1, BCL6, and NCOA3 might provide additional molecule/pathway-based therapeutic options for SCNECs.
Unexpectedly, BRCA1 and BRCA2 somatic mutations were discovered in 2 tumors. BRCA1 p.T367I appears to be a novel mutation with unknown function. In contrast, BRCA2 c.3545_3546 TT deletion leads to frameshift mutation and translation termination. Interestingly, BRCA1 interacts with HPV oncoproteins through which E6 and E7 antagonize the ability of BRCA1 to inhibit c-Myc E-box-mediated transactivation and human telomerase reverse transcriptase promoter activity. 55 The poly (ADP-ribose) polymerase (PARP) inhibitors have been successfully used for the treatment of germline BRCAmutated ovarian cancer patients. [56] [57] [58] Importantly, patients with a somatic BRCA mutation also show benefit from treatment with PARP inhibitors. 59, 60 Identification of somatic BRCA mutations in patients with SCNEC allows testing of PARP inhibitors to treat this aggressive tumor.
Surprisingly, clinically relevant and actionable somatic mutations in this gene panel were not identified in 2 tumors. We suspect genetic alterations such as gene overexpression and/or inactivation, copy number variation, and DNA and/ or histone-related epigenetic regulation, other than somatic mutations, may play a critical role in the oncogenic process of these tumors.
Our results are quite different from a recent study that evaluated the mutation profile for 5 tumor-normal paired cervical SCNECs using whole exome sequencing. 22 Recurrent mutations in ATRX and ERBB4 as well as Akt/ mTOR pathway genes NF1, PTEN, RICTOR, and TSC1/ 2 were identified in that study. Although involving the Akt/mTOR pathway, this mutation profile is different from that of the majority of high-risk HPV-related tumors which commonly contain recurrent somatic driver mutations in PIK3CA, KRAS, TP53, ERBB2, and MAPK1. 19 Since the recurrent somatic TSC2, NF1, and PTEN mutations identified in that study were also present in neuroendocrine tumors of other sites, but not in high-risk HPV-related cervical tumors, the origin and genetic background of SCNEC of the cervix are thought to be different from those of cervical high-risk HPV-related tumors. 22 In contrast, our findings support that the genetic landscape in the initiation and development of cervical SCNEC is similar to that of other high-risk HPV-related cervical tumors. 46 In summary, utilizing a targeted next-generation gene sequencing technology, our study identified and confirmed recurrent genetic alterations involving the MAPK, PI3K/AKT/ mTOR, and p53/BRCA pathways in cervical SCNECs. The presence of genetic alterations that are amenable to targeted therapy, individually or in combination, in cervical SCNECs offers the potential for individualized management strategies for treatment of this aggressive tumor.
